| Product Code: ETC9959328 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Antimicrobial Resistance Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Antimicrobial Resistance Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Antimicrobial Resistance Market - Industry Life Cycle |
3.4 United States (US) Antimicrobial Resistance Market - Porter's Five Forces |
3.5 United States (US) Antimicrobial Resistance Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 United States (US) Antimicrobial Resistance Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 United States (US) Antimicrobial Resistance Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.8 United States (US) Antimicrobial Resistance Market Revenues & Volume Share, By Pathogen, 2021 & 2031F |
4 United States (US) Antimicrobial Resistance Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of infectious diseases |
4.2.2 Growing awareness about the impact of antimicrobial resistance on public health |
4.2.3 Technological advancements in diagnostics and treatment methods |
4.3 Market Restraints |
4.3.1 Overuse and misuse of antibiotics |
4.3.2 Lack of new antibiotics development |
4.3.3 Regulatory challenges in approving new antimicrobial drugs |
5 United States (US) Antimicrobial Resistance Market Trends |
6 United States (US) Antimicrobial Resistance Market, By Types |
6.1 United States (US) Antimicrobial Resistance Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Complicated Urinary Tract Infections (cUTI), 2021- 2031F |
6.1.4 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Blood stream infections, 2021- 2031F |
6.1.5 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Acute bacterial skin and skin structure infections (ABSSSI), 2021- 2031F |
6.1.6 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), 2021- 2031F |
6.1.7 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Community acquired pneumonia (CAP), 2021- 2031F |
6.1.8 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
6.2 United States (US) Antimicrobial Resistance Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Combination therapies, 2021- 2031F |
6.2.3 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Tetracyclines, 2021- 2031F |
6.2.4 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Cephalosporins, 2021- 2031F |
6.2.5 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Glycopeptides and Lipoglycopeptides, 2021- 2031F |
6.2.6 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Oxazolidinones, 2021- 2031F |
6.2.7 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Antimicrobial Resistance Market, By Mechanism of Action |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Protein Synthesis Inhibitors, 2021- 2031F |
6.3.3 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Cell Wall Synthesis Inhibitors, 2021- 2031F |
6.3.4 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Antimicrobial Resistance Market, By Pathogen |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Klebsiella pneumoniae, 2021- 2031F |
6.4.3 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Pseudomonas aeruginosa, 2021- 2031F |
6.4.4 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Staphylococcus aureus, 2021- 2031F |
6.4.5 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Enterococcus Spp, 2021- 2031F |
6.4.6 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Escherichia coli, 2021- 2031F |
6.4.7 United States (US) Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
7 United States (US) Antimicrobial Resistance Market Import-Export Trade Statistics |
7.1 United States (US) Antimicrobial Resistance Market Export to Major Countries |
7.2 United States (US) Antimicrobial Resistance Market Imports from Major Countries |
8 United States (US) Antimicrobial Resistance Market Key Performance Indicators |
8.1 Percentage of healthcare facilities implementing antimicrobial stewardship programs |
8.2 Number of reported cases of antibiotic-resistant infections |
8.3 Investment in research and development for new antimicrobial agents |
9 United States (US) Antimicrobial Resistance Market - Opportunity Assessment |
9.1 United States (US) Antimicrobial Resistance Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 United States (US) Antimicrobial Resistance Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 United States (US) Antimicrobial Resistance Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.4 United States (US) Antimicrobial Resistance Market Opportunity Assessment, By Pathogen, 2021 & 2031F |
10 United States (US) Antimicrobial Resistance Market - Competitive Landscape |
10.1 United States (US) Antimicrobial Resistance Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Antimicrobial Resistance Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here